Overview

L-arginine Study for Persistent Symptoms of Schizophrenia

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this research is to see if daily combination treatment of L-arginine and Kuvan changes brain chemistry in people experiencing schizophrenia as measured by MRS brain scans.
Phase:
Phase 2
Details
Lead Sponsor:
University of Massachusetts, Worcester